Delivering Precision Medicine in Oncology Today and in Future – promises and challenges of delivering personalised cancer medicine

Published in Annals of Oncology by members of the ESMO Personalised Medicine Task Force and the ESMO Board, the paper elaborates on how to define personalised cancer medicine, tumour heterogeneity, molecular evolution and drug resistance plus precision diagnostics and predictive biomarkers of therapeutic response.

Risk of the New EU Data Protection Regulation: an ESMO position paper endorsed by the European oncology community

A call to assure that all forms of public health research will survive and be able to function within the current safeguards, without adding the nearly impossible burden of re-consenting each patient, every time, for every single project, which could irreversibly slow down the accelerated pace that cancer research has gained over the past decades.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings